SRR13780258
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.460
- PANCREAS_BETA_CELLS+0.410
- IL6_JAK_STAT3_SIGNALING+0.360
- INTERFERON_GAMMA_RESPONSE+0.350
- INTERFERON_ALPHA_RESPONSE+0.270
- TNFA_SIGNALING_VIA_NFKB+0.270
- INFLAMMATORY_RESPONSE+0.250
- APICAL_SURFACE+0.240
- KRAS_SIGNALING_DN+0.230
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- E2F_TARGETS-0.690
- G2M_CHECKPOINT-0.650
- MYC_TARGETS_V1-0.510
- MITOTIC_SPINDLE-0.480
- MTORC1_SIGNALING-0.430
- DNA_REPAIR-0.420
- OXIDATIVE_PHOSPHORYLATION-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- MYC_TARGETS_V2-0.360
- PROTEIN_SECRETION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ee0e68bf-7fa0-4edc-a9df-30a63c2db34a | — | — | 0.912 |
| 2 | MBCProject_0026_T2_RNA | — | E | 0.893 |
| 3 | MNG450 | — | — | 0.891 |
| 4 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.883 |
| 5 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.874 |
| 6 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.872 |
| 7 | SRR26320079 | — | — | 0.868 |
| 8 | SRR25617853 | — | D | 0.864 |
| 9 | 6b907244-c173-4e29-a163-24258a430477 | — | — | 0.860 |
| 10 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |